Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer
Differences in the effect of gefitinib and chemotherapy on tumor burden in non‐small cell lung cancer remain to be fully understood. Using a Bayesian hierarchical model of tumor size dynamics, we estimated the rates of tumor growth and treatment resistance for patients in the Iressa Pan‐Asia Study s...
Saved in:
Main Authors: | Mario Nagase (Author), Sergey Aksenov (Author), Hong Yan (Author), James Dunyak (Author), Nidal Al‐Huniti (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2020-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
by: Nidal Al‐Huniti, et al.
Published: (2020) -
Optimizing response to gefitinib in the treatment of non-small-cell lung cancer
by: Pietro Carotenuto, et al.
Published: (2011) -
Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer
by: Honggang Wang, et al.
Published: (2017) -
Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
by: Wang Y, et al.
Published: (2022) -
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
by: M Tiseo, et al.
Published: (2010)